LB Pharmaceuticals Q2 FY26 net loss widens to $51.6 million
LBRX•Pipeline timeline
Phase 3 NOVA-2 LB-102 schizophrenia topline data is expected in H1 2027, with a pre-NDA meeting targeted for H2 2027.
Cash position and runway
Cash, equivalents, and marketable securities totaled $327.8 million at June 30, excluding a July $150 million private placement; runway projected beyond Q2 2029.
Quarterly results and expenses
LB Pharmaceuticals posted a Q2 net loss of $51.6 million, widening from $4.9 million a year earlier.
- R&D costs climbed to $44.1 million from $2.4 million, driven mainly by higher Phase 3 LB-102 schizophrenia trial spending.
- G&A expense rose to $9.8 million from $2.4 million, on higher stock-based compensation, professional fees, and headcount.
